GlassScriptPhysician profile
Danielle Sara Applebaum
NPI 1073931812
$20,000.75
in general payments reported to CMS, 2019-2025
33 companies · $4,556 in 2025
The $4,556 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $1,138 · 2021: $2,041 · 2022: $2,837 · 2023: $2,779 · 2024: $4,963 · 2025: $4,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,099.55 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $2,361.90 | 2024-2025 | Daxxify, Daxi |
| Abbvie INC. | $2,148.69 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Novartis Pharmaceuticals Corporation | $1,655.22 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,652.08 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $1,517.94 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $1,147.73 | 2019-2025 | |
| Lilly USA, LLC | $1,059.55 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,026.78 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $935.99 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Mayne Pharma Commercial LLC | $680.70 | 2019-2025 | |
| Incyte Corporation | $668.86 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $656.78 | 2023-2025 | Zoryve |
| Pfizer INC. | $508.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $439.54 | 2022-2025 | Sotyktu, Sprycel |
| Dermavant Sciences, INC. | $381.42 | 2022-2024 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $370.70 | 2019-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $343.34 | 2019-2025 | |
| Merz North America, INC. | $338.45 | 2020-2024 | |
| Amgen INC. | $311.72 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $278.83 | 2022-2025 | Bimzelx, Cimzia |
| Encore Dermatology INC. | $205.23 | 2019-2020 | |
| Hill Dermaceuticals, INC. | $204.16 | 2022-2023 | Tolak |
| Vyne Pharmaceuticals INC. | $201.29 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $152.00 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Solta Medical, A Division of Bausch Health US, LLC | $151.88 | 2024 | |
| Organon LLC | $149.81 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $109.61 | 2021 | |
| Almirall LLC | $108.38 | 2020-2025 | Seysara |
| Botanix Sb INC | $107.10 | 2025 | Sofdra |
| Allergan, INC. | $55.87 | 2019-2021 | |
| Epi Health, LLC | $37.87 | 2022 | |
| Kerecis Limited | $21.36 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Celgene Corporation | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.